论文部分内容阅读
目的探讨布地奈德和异丙托溴铵联合雾化吸入治疗慢性阻塞性肺疾病的临床疗效。方法 84例慢性阻塞性肺疾病患者随机分为观察组和对照组,各42例,所有患者入组后均给予吸氧、抗感染等综合治疗,观察组患者在此基础上雾化吸入布地奈德和异丙托溴铵,比较两组患者的治疗效果以及肺功能改善指标。结果观察组治疗有效率显著高于对照组,差异有统计学意义(P<0.05);观察组患者肺功能指标一秒用力呼气容积(FEV1)和FEV1/用力肺活量(FVC)改善效果显著优于对照组,差异有统计学意义(P<0.05)。结论在常规治疗基础上雾化吸入布地奈德和异丙托溴铵可显著提升慢性阻塞性肺疾病患者的治疗效果,改善患者肺功能指标,值得在临床上使用。
Objective To investigate the clinical efficacy of budesonide combined with ipratropium bromide in the treatment of chronic obstructive pulmonary disease. Methods Eighty-four patients with chronic obstructive pulmonary disease were randomly divided into observation group and control group, with 42 cases in each group. All patients were given combined therapy of oxygen and anti-infection after inhalation. In the observation group, budesonide De and ipratropium bromide, the two groups were compared the therapeutic effect and lung function improvement indicators. Results The effective rate of treatment in observation group was significantly higher than that in control group (P <0.05). The improvement of pulmonary function parameters FEV1 and FEV1 / FVC in observation group was significant In the control group, the difference was statistically significant (P <0.05). Conclusion Inhalation of budesonide and ipratropium bromide on the basis of routine treatment can significantly improve the therapeutic effect of patients with chronic obstructive pulmonary disease and improve the pulmonary function indicators, which is worth to be used clinically.